NVO
Novo Nordisk A/S
Stock
$37.32−0.08 (−0.21%)Close Oct 2, 2026
Cash flow statement
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | DKK 119.1B | DKK 121.0B | DKK 108.9B | DKK 78.9B | DKK 55.0B | DKK 52.0B | DKK 46.8B |
| Capital expenditures | DKK 60.1B | DKK 47.2B | DKK 25.8B | DKK 12.1B | DKK 6.3B | DKK 5.8B | DKK 8.9B |
| Free cash flow | DKK 59.0B | DKK 73.8B | DKK 83.1B | DKK 66.7B | DKK 48.7B | DKK 46.1B | DKK 37.9B |
| Stock-based compensation | DKK 1.4B | DKK 2.3B | DKK 2.1B | DKK 1.5B | DKK 1.0B | DKK 823M | DKK 363M |
| Buybacks | DKK 1.4B | DKK 20.2B | DKK 29.9B | DKK 24.1B | DKK 19.4B | DKK 16.9B | DKK 15.3B |
| Dividends paid | DKK 51.8B | DKK 44.1B | DKK 31.8B | DKK 25.3B | DKK 21.5B | DKK 20.1B | DKK 19.4B |
| Free cash flow margin | 19.1% | 25.4% | 35.8% | 37.7% | 34.6% | 36.3% | 31.0% |